Bladder Cancer Without Bladder Removal: Your 2026 Options

Since 2016, patient death rates due to bladder cancer have been declining by 1.4% a year, thanks to early detection and improved bladder treatments. Now, novel treatments are dedicated to saving the actual bladder’s life.

The rate of total bladder removals, or cystectomies, declined by 17% from 1988 to 2000 (most recent year). Now, as researchers develop breakthrough medications and cancer-marking tests to treat the disease, less-invasive treatments are becoming more widely available for early-stage bladder cancer patients, 52% of whom have refused total cystectomies.

Learn more about bladder cancer causes, diagnosis, and treatment pathways

In 2026, Michigan Institute of Urology began offering Inlexzo, a newer bladder-preserving treatment appropriate for some patients. Patients whose cancer haven’t responded to standard treatment, Bacillus Calmette-Guerin (BCG)—which we’ll discuss later in this article—may be possible candidates. Inlexzo is a small device placed in the bladder that slowly releases chemotherapy over several weeks.

Inlexzo’s approval by the FDA in 2025 underscores a turning point in the progress of bladder-preserving cancer treatments. In a clinical study supporting FDA approval, 82% of patients achieved a complete response, and 51% of responders remained in complete response for at least one year. Individual results can vary, and close follow-up remains essential. Other bladder-preserving new treatments include immunotherapies and gene therapies to treat non muscle invasive bladder cancers that have not reached the muscle in the bladder wall.

This blog explains these options, who is eligible, and how the treatments work.

Why Cancer Might Require Bladder Removal

Your bladder is a hollow organ with one important job: to store urine. The bladder walls consist of many layers, including muscles that squeeze out urine. The kidneys, liver, and urinary tract all depend on its ability to do this in order for them to function well.

Sometimes, the cells in the bladder wall begin to act abnormally, dividing and growing out of control to form an invasive tumor. These malignancies are classified by their growth patterns. In non-invasive bladder cancer, 90% of the tumors are papillary – wart-like growths with stems attached to the tissue.

In muscle-invasive cancers, the tumor has grown into deeper layers of the bladder wall, including the muscle layer. Should this occur, the blood vessels in the wall enable the cancer to move faster and threaten surrounding organs, so complete bladder removal is advised.

However, if the cancer has not yet penetrated the bladder wall – non-muscle invasive bladder cancer – your bladder can be saved.

Symptoms of bladder cancer include:

• An increased and often urgent need to urinate.
• Difficult passing urine.
• Blood in the urine (hematuria).
• Bladder pain (lower abdomen).

How Inlexzo and Other Direct-Feed Drugs Work

Researchers are continuously researching gene and protein changes in cancerous bladder cells to inform treatment decisions. These treatments include certain drug therapies for bladder cancer that are fed directly into the bladder through a urinary catheter (small tube).

This process, which bypasses oral or blood-injected medication, is called intravesical therapy.

Today, several immunotherapies and chemotherapies can be delivered straight to the bladder through a catheter, including the following.

Intravesical Immunotherapies

Immunotherapies are a class of medications engineered to enable a patient’s own immune system to identify and destroy cancer cells.

Bacillus Calmette-Guerin (BCG) – For early-stage bladder cancer, this liquid vaccine is made from a germ related to a tuberculosis-causing germ. When administered, it triggers the patient’s immune system cells to attack the cancer cells without causing serious illness.

Nadofaragene firadenovec (Adstiladrin) – Considered a form of gene therapy, this drug is derived from a virus containing a gene that makes an important immune system protein. When introduced into the bladder, the medication delivers the gene to the cells in the bladder wall, which then produce more of the protein, supporting the immune system’s ability to attack the cancer.

Nogapendekin alfa inbakicept (Anktiva) – This medication is designed to make the molecules in your cells act in a certain way (a receptor agonist). In the case of bladder cancer treatment, it activates some of the body’s immune cells, including natural killer cells and T cells, to attack the cancer cells.

Intravesical Chemotherapy

This treatment approach feeds a chemotherapy drug right into the bladder, using a catheter, to attack active cancer cells head-on. Options include:

Inlexzo (gemcitabine intravesical system) – Inlexzo is designed for patients with a form of non-muscle invasive bladder cancer that is higher risk and requires close monitoring (carcinoma situ). The system involves a small pretzel-shaped implant, infused with a chemotherapy drug, that slow-releases treatment over a 21-day period. By delivering the chemo directly into the tumor, the Inlexzo system can enhance concentration and protect surrounding tissue from exposure. In a clinical study, 82% of patients produced no signs of bladder cancer after their treatment; 51% were cancer free for at least one year.

On Jan. 23, a surgical team at Michigan Institute of Urology performed the first Inlexzo procedure in the state of Michigan.

Zusduri– This form of chemotherapy drug was developed to treat the recurrence (return) of non-muscle invasive bladder cancer in patients who have undergone minimally invasive surgery to remove small tumors (transurethral resection of the bladder). Once the liquid is delivered to the bladder through a catheter, it transforms into a gel that stays on the bladder wall for several hours, killing the DNA function in cancer cells. In most cases, it is administered once a week for six weeks.

For the population of patients with early-stage bladder cancer, these breakthroughs represent a chance to avoid total bladder removal and the side effects. Read about other innovations in bladder cancer treatments on our blog.

What to Expect After Bladder Treatment

After treatment, ongoing surveillance is important because non-muscle invasive bladder cancer can recur. Follow-up may include cystoscopy, urine testing, imaging, and other evaluations based on your doctor’s recommendations

To lower your risks of the cancer recurring, avoid tobacco smoke and maintain a healthy body weight. Some studies link excess body weight with the risk of non-muscle invasive bladder cancer.

Lastly, you should plan to enjoy your post-treatments days, months, and years. According to the American Cancer Society, the 5-year relative survival rate is about 98% for non-invasive (in situ) bladder cancer and about 73% for localized bladder cancer.

If you experience any bladder cancer symptoms such as blood in your urine, request an appointment with a urologist quickly. You can find a specialist at one of our convenient locations across Michigan here